Autonomix Medical (AMIX) investor relations material

Company overview and business model

• Development-stage medical device company focused on technologies for sensing and treating nervous system disorders.

• Platform integrates high-sensitivity neural signal detection with targeted RF ablation for a “sense, treat, verify” approach.

• Proprietary catheter-based system aims to improve precision in nerve-targeted therapies, initially targeting pain associated with pancreatic cancer.

• Early clinical studies showed variable outcomes, prompting further refinement of clinical and procedural approaches.

• Potential applications include other visceral pain conditions, hypertension, cardiovascular disease, and nerve-related disorders.

Financial performance and metrics

• Reverse stock split (1:21) reduced outstanding shares from 11,409,344 to 542,349 as of June 24, 2026.

• Received approximately $2.6 million in gross proceeds from the exercise of Series C warrants in July 2026.

• Financial statements for fiscal years ended March 31, 2026 and 2025 audited by Forvis Mazars, LLP, with a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Proceeds from any cash exercise of Series D warrants (up to $4.9 million) will be used for working capital purposes.

• Management has broad discretion over timing and application of proceeds; actual receipt depends on warrant exercise.